11 January 2023 - For the third time in less than a year, a group of law makers is urging the Biden administration to use a controversial provision of federal law to widen access to a pricey cancer medicine, an issue that has festered ever since cancer patients petitioned the federal government.

The medicine in their crosshairs is the Xtandi prostate cancer drug, which last year had a $156,000 list price, according to Elsevier Health.

Read Stat News article